Patents by Inventor Natalie Bowerman

Natalie Bowerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230060095
    Abstract: The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs.
    Type: Application
    Filed: January 22, 2021
    Publication date: February 23, 2023
    Inventors: Natalie Bowerman, Johanna Hansen
  • Publication number: 20220324939
    Abstract: The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen Melanoma-Associated Antigen A4 (MAGE-A4) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs. The present invention provides T cell receptors (TCRs) that were generated against a MAGE-A4 peptide antigen in the context of MHC (HLA-A2). The unique TCR sequences identified have shown specific binding to the small peptide MAGE-A4 presented in the groove of an HLA molecule and exhibited activation of T cells in a reporter assay.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 13, 2022
    Inventors: Natalie Bowerman, Cagan Gurer, Johanna Hansen
  • Publication number: 20210403527
    Abstract: The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) peptides, as well as therapeutic and diagnostic methods of using those isolated TCRs.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 30, 2021
    Inventors: Robert Babb, Natalie Bowerman, Gang Chen, Cagan Gurer, Johanna Hansen, Wen-Yi Lee, Thomas Meagher, David Suh